The antigenicity of nonspecific immunostimulator BARODON, a newly developed drug, was investigated by tests for passive cutaneous anaphylaxis (PCA) and active systemic anaphylaxis (ASA) in mice and guinea pigs. In ASA test using guinea pigs, there were no significant clinical symptoms in all individuals of low (0.3%) and high (3%) dose of both groups treated with only BARODON and cotreated with BARODON and adjuvant group. In PCA test, blue spots of Evan´s were observed from 2^6 to 2^10 in homologous group and from 2^2~2^5 dilution rate in geterologous group of VSA treated positive control group. However, intradermal sensitization with antiserum obtained from low (0.3%) and high (3%) dose of BARODON only treatment group and treated-with-adjuvant group, followed by intravenous injection of respective antigen and Evan´s blue mixture (1:1) showed no blue spot observed.
In conclusion, BARODON, as showed in ASA and PCA test, did not cause anaphylatic shock when treated 3 and 10 times higher than clinically intended dose, nor induce IgE, so that might not have antigenic properties in mice and guinea pigs.
|